Search - tctmd.com

Displaying 101 - 120 of 135

Sort: Relevancy | Date

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

News Daily News

Synopsis of New Hypertension Guidelines Renews Concerns and Controversy

January 22, 2018

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

News Daily News

Symptomatic Myocardial Ischemia but No Obstructive CAD: Some Drugs Work, Others Don’t, Review Finds

January 18, 2018

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

TCTMD’s Top 10 Most Popular Stories for October 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2017

October 29, 2017

Generic ARBs Linked to Increased Adverse Events

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

TCTMD’s Top 10 Most Popular Stories for September 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2017

September 30, 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On, With Hotly Anticipated Trials

News Opinion Editor's Corner ESC 2017

ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On

August 18, 2017

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

News Daily News

Fibrinolytic Agents for STEMI: Meta-analysis Explores the Differences

August 18, 2017

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

News Daily News

CKD Patients Undergoing PCI Much Less Likely to Receive Potent P2Y12 Inhibition

Michael O'Riordan

August 04, 2017

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

News Daily News

Registry Study Supports Curbing Cholesterol Screening for Young Adults Because of Low Overall Risk

Yael L. Maxwell

May 15, 2017

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

News Daily News

Rivaroxaban Appears to Protect Against MI in Older Men With A-fib, but Not in Women

May 11, 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

March 18, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

December 30, 2016

News Daily News

New USPSTF Guidelines Recommend Statins in ‘Appropriately Selected’ Primary-Prevention Patients

Michael O'Riordan

November 13, 2016

News Conference News ESC 2016

Optimal Approach for BP Lowering Debated Amid New J-Curve Signals in Stable CAD

September 09, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.